Rheumatology International

, Volume 25, Issue 3, pp 211–214 | Cite as

Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases

  • Sevil KamaliEmail author
  • Ayse Cefle
  • Mehmet Sayarlioglu
  • Ahmet Gul
  • Murat Inanc
  • Lale Ocal
  • Orhan Aral
  • Meral Konice
Original Article


We aimed to investigate the efficacy and safety profile of high-dose intravenous immunoglobulin (HD-IVIG) therapy in patients with severe systemic lupus erythematosus (SLE), inflammatory muscle disease (IMD), Wegener’s granulomatosis (WG), and/or concurrent infection who failed to respond to standard therapies. We evaluated the records of eight patients with SLE, eight with IMD, and four with WG who were treated with HD-IVIG (2 g/kg per month for 1–12 months) for active disease in 19 patients and concurrent infection in three (mycobacterial in two with SLE and cytomegaloviral in one with WG). Systemic lupus erythematosus disease activity index (SLEDAI) scores before and after HD-IVIG were statistically analysed. Remission was achieved in 14 cases (70%). The SLEDAI scores significantly decreased in patients with SLE (P=0.02). No serious side effect was observed. High-dose IVIG may be used as an adjunctive treatment in connective tissue diseases that do not respond to standard therapies or as alternative treatment for patients with concurrent severe infections or for whom immunosuppressives are contraindicated.


Inflammatory muscle disease Intravenous immunoglobulin Wegener’s granulomatosis 


  1. 1.
    Imbach P, Wagner H, Berchtold W et al (1985) Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet 2:464CrossRefPubMedGoogle Scholar
  2. 2.
    Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J et al (1991) A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324:1633–1639PubMedGoogle Scholar
  3. 3.
    Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM (1991) Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 91:169–172PubMedGoogle Scholar
  4. 4.
    Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325:1487–1498Google Scholar
  5. 5.
    Choy EH, Isenberg DA (2002) Treatment of dermatomyositis and polymyositis. Rheumatology 411:7–13CrossRefGoogle Scholar
  6. 6.
    Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, Maisonobe T, Eymard B, Herson S (2002) Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46:467–474CrossRefPubMedGoogle Scholar
  7. 7.
    Collet E, Dalac S, Maerens B, Courtois JM, Izac M, Lambert D (191994) Juvenile dermatomyositis: treatment with intravenous gammaglobulin. Br J Dermatol 130:231–234Google Scholar
  8. 8.
    Levy Y, Sherer Y, Ahmed A, Langevitz P, George J et al (1999) A study of 20 patients with intravenous immunoglobulin—clinical and serologic response. Lupus 8:705–712CrossRefPubMedGoogle Scholar
  9. 9.
    Levy Y, Sherer Y, George J, Rovensky J, Lukac J et al (2000) Intravenous immunoglobulin treatment of lupus nephritis. Semin Arthritis Rheum 29:321–327PubMedGoogle Scholar
  10. 10.
    Palla R, Cirami C, Bionda A et al (1986) High dose intravenous gammaglobulin for membranous nephropathy. Clin Nephrol 26:314Google Scholar
  11. 11.
    Boletis JN, Ioannidis JPA, Boki KA, Moutsopoulos HM (1999) Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 354:569–570CrossRefPubMedGoogle Scholar
  12. 12.
    Carreras LO, Perez GN, Vega HR, Casavilla F (1988) Lupus anticoagulant and recurrent fatal loss: successful treatment with gammaglobulin. Lancet 2:393–394CrossRefGoogle Scholar
  13. 13.
    Sherer Y, Levy Y, Shoenfeld Y (2000) Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology 39:421–426CrossRefPubMedGoogle Scholar
  14. 14.
    Branch D, Ware MD, Peaceman AM et al (2000) A multicenter, placebo controlled pilot study of intravenous treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 182:122–127PubMedGoogle Scholar
  15. 15.
    Jayne DRW, Lockwood CM (1996) Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 35:1150–1153CrossRefPubMedGoogle Scholar
  16. 16.
    Jayne DRW, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93:433–49CrossRefPubMedGoogle Scholar
  17. 17.
    Permal S, Wechsler B, Cabane J, Perrot S, Blum L, Imbert JC (1995) Treatment of Still disease in adults with intravenous immunoglobulins. Rev Med Interne 16:250–254CrossRefPubMedGoogle Scholar
  18. 18.
    Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345:747–755PubMedGoogle Scholar
  19. 19.
    Tan EM (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMedGoogle Scholar
  20. 20.
    Leavitt RY et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107PubMedGoogle Scholar
  21. 21.
    Dalakas MC (1988) A classification of polymyositis and dermatomyositis. In: Dalakas MC (ed) Polymyositis and dermatomyositis. Butterworth, Boston, pp 1–16Google Scholar
  22. 22.
    Pyne D, Ehrenstein M, Morris V (2002) The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 41:367–374CrossRefPubMedGoogle Scholar
  23. 23.
    Maier WP, Gordon DS, Howard RF, Saleh MN, Miller SB et al (1990) Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum 33:1233–1239PubMedGoogle Scholar
  24. 24.
    Jacobs P, Wood L (1989) The comparison of gammaglobulin to steroids in treating adult immune thrombocytopenia: an interim analysis. Blut 59:92–95PubMedGoogle Scholar
  25. 25.
    Sherer Y, Levy Y, Langevitz P, Lorber M, Fabrizzi F, Shoenfeld Y (1999) Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 18:170–173CrossRefPubMedGoogle Scholar
  26. 26.
    Lafferty TE, Smith JB, Schuster SJ, De Horatius RJ (1997) Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Arthritis Rheum 40:775–778PubMedGoogle Scholar
  27. 27.
    Aharon A, Levy Y, Bar-Dayan Y, Afek A, Zandman-Goddard G, Skurnik Y, Fabrizzi F, Shoenfeld Y (1997) Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 6:408–411PubMedGoogle Scholar
  28. 28.
    Kurth R, Haas WH (2002) Epidemiology, diagnostic possibilities, and treatment of tuberculosis. Ann Rheum Dis 61 [Suppl 2]:ii59–ii61Google Scholar
  29. 29.
    Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51 [6 Suppl 5]:S37–S45Google Scholar
  30. 30.
    Hamilos DL, Christensen J (1991) Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol 88:823–824PubMedGoogle Scholar
  31. 31.
    Levy Y, Sherer Y, George J, Langevitz P, Ahmed A, Bar-Dayan Y, Fabrizzi F, Terryberry J, Peter J, Shoenfeld Y (1999) Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 119:231–238CrossRefPubMedGoogle Scholar
  32. 32.
    Epstein JS, Gaines A, Kapit R, Pierce R, Potter R, Varricchio F (1999) Important drug information: immune globulin intravenous (human). Int J Trauma Nurs 5:139–140PubMedGoogle Scholar
  33. 33.
    Hashkes PJ, Lovell DJ (1996) Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 14:673–675PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Sevil Kamali
    • 1
    • 2
    Email author
  • Ayse Cefle
    • 1
  • Mehmet Sayarlioglu
    • 1
  • Ahmet Gul
    • 1
  • Murat Inanc
    • 1
  • Lale Ocal
    • 1
  • Orhan Aral
    • 1
  • Meral Konice
    • 1
  1. 1.Department of Rheumatology, Division of Internal Medicine, Medical FacultyIstanbul UniversityIstanbulTurkey
  2. 2.Týp FakültesiÝstanbul ÜniversitesiIstanbulTurkey

Personalised recommendations